Eybna with Matthew Mograbi Director of US Operations

Eybna with Matthew Mograbi Director of US Operations today on Blunt Business only on Cannabis Radio. Our next guest joins us representing a pioneering technology company and terpene manufacturer with two locations in California and in Israel, is expanding its U.S. footprint with the opening of new production and R&D facilities as well as strategic partnerships with leading companies across the consumer packaged goods supply chain. With Vertosa Labs, for product innovation and expanding access to the experiential and therapeutic potential of cannabis-based ingredients.


With Endocanna and their EndoAligned compositions, which identify the proper CBD to THC ratio, along with the dominant cannabinoid and terpene profiles that work with a specific person’s DNA, enabling their consistent production and supply in scale to meet growing demands. And with Loop Labs to develop an innovative delivery system for use with Eybna’s proprietary NT-VRL™ terpene formulation, which is currently undergoing testing as a potential treatment and preventive solution of viral infections, including COVID-19. In addition to growing its product offerings in the U.S., the overarching goals of Eybna’s R&D initiatives are to understand and unlock the full potential of cannabis phytochemicals and make them accessible for broader populations worldwide. Their team of Ph.D. scientists currently has 11 research studies in progress, including studies suggesting Eybna’s terpene formulation, NT-VRL™, may play a role in the effective management of COVID-19 symptoms and has the potential to serve as an antiviral preventative to human coronaviruses as well. The formulation demonstrated potential in-vitro efficacy for treating inflammatory conditions such as the deadly cytokine storm syndrome found in COVID-19 patients.